StockData

Indaptus Therapeutics, Inc. (INDP) stock

INDPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 5/30
$3.32−0.13 (-3.77%)

Close on Nov 17, 2026Market cap $442.37MP/E –Yield –

Indaptus Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Indaptus Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$14.70M. For fiscal 2025 it was -$14.82M. The highest annual figure on record is -$3.32M in fiscal 2020.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$14.82M–
FY2024Dec 31, 2024-$12.32M–
FY2023Dec 31, 2023-$13.41M–
FY2022Dec 31, 2022-$13.08M–
FY2021Dec 31, 2021-$11.29M–
FY2020Dec 31, 2020-$3.32M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$1.93M–
Q1 FY2026Mar 31, 2026-$7.01M–
Q4 FY2025Dec 31, 2025-$3.19M–
Q3 FY2025Sep 30, 2025-$2.57M–
Q2 FY2025Jun 30, 2025-$4.02M–
Q1 FY2025Mar 31, 2025-$5.05M–
Q4 FY2024Dec 31, 2024-$3.40M–
Q3 FY2024Sep 30, 2024-$2.51M–
Q2 FY2024Jun 30, 2024-$2.48M–
Q1 FY2024Mar 31, 2024-$3.94M–
Q4 FY2023Dec 31, 2023-$2.60M–
Q3 FY2023Sep 30, 2023-$3.73M–
Q2 FY2023Jun 30, 2023-$2.11M–
Q1 FY2023Mar 31, 2023-$4.96M–
Q4 FY2022Dec 31, 2022-$2.21M–
Q3 FY2022Sep 30, 2022-$4.60M–
Q2 FY2022Jun 30, 2022-$3.15M–
Q1 FY2022Mar 31, 2022-$3.12M–
Q4 FY2021Dec 31, 2021-$3.54M–
Q3 FY2021Sep 30, 2021-$5.63M-226.5%
Q2 FY2021Jun 30, 2021-$1.29M–
Q1 FY2021Mar 31, 2021-$825.58K–
Q4 FY2020Dec 31, 2020-$957.03K–
Q3 FY2020Sep 30, 2020$4.45M–

More Indaptus Therapeutics figures

See a number that looks wrong?